TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8753109

Group type: EXPERIMENTAL
Intervention: G-CSF (50 microns/m2, subcutaneously) administered when leukocyte count is ≤ 1000/mm3
Number of subjects: 66

Group type: COMPARATOR
Intervention: G-CSF (50 microns/m2, subcutaneously) administered when leukocyte count is between 1000/mm3 and 2000/mm3
Number of subjects: 66
Study: 1864255

Group type: EXPERIMENTAL
Intervention: Citalopram/Lithium
Number of subjects: 14

Group type: COMPARATOR
Intervention: Citalopram/Placebo
Number of subjects: 14
Study: 6612689

Group type: EXPERIMENTAL
Intervention: High saturated fat diet (P/S ratio 1:8)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: High polyunsaturated fat diet (P/S ratio 4:1)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Colestipol (20 gm/day)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 30596338

Group type: EXPERIMENTAL
Intervention: Sprint interval training (5 to 6, 30 second 'all out' running sprints, 3 times per week for 4 weeks)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Sprint interval training
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (normal physical education lessons)
Number of subjects: 56
Study: 28283732

Group type: EXPERIMENTAL
Intervention: half-dose photodynamic therapy (hd-PDT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 689 nm laser therapy (689-LT)
Number of subjects: 40
Study: 25308628

Group type: EXPERIMENTAL
Intervention: Moderate-intensity endurance exercise
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Resistance training added to both groups after 3 months
Number of subjects: 19
Study: 23871475

Group type: EXPERIMENTAL
Intervention: HF disease management program (HF-DMP)
Number of subjects: 12
Study: 21307009

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 µg kg(‐1) i.v. over 20 min followed by 0.7 µg kg(‐1) h(‐1) infusion for 190 min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Morphine hydrochloride (0.10 mg kg(‐1) i.v. over 20 min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 12
Study: 19194156

Group type: EXPERIMENTAL
Intervention: Sugammadex (2.0 mg/kg)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 16401664

Group type: EXPERIMENTAL
Intervention: Diphenhydramine 100 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lorazepam 1.5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (50, 75, and 100 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lorazepam 0.5 mg
Number of subjects: 12
Study: 15340535

Group type: EXPERIMENTAL
Intervention: IFN alpha‐2b 3MU added to ongoing lamivudine, daily for one month, then every other day for five months
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Injectable oxymatrine 60 mg daily for three months, followed by oral oxymatrine every day for three months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ongoing treatment with lamivudine alone
Number of subjects: 40
Study: 10931126

Group type: EXPERIMENTAL
Intervention: Portable domestic dehumidifier
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Behavioural programme
Number of subjects: 76

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 76
Study: 9924298

Group type: EXPERIMENTAL
Intervention: 99mTc‐DTPA gel
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 99mTc‐carbon gel
Number of subjects: 12

Group type: COMPARATOR
Intervention: saline
Number of subjects: 12
Study: 7752839

Group type: EXPERIMENTAL
Intervention: Hard gelatin capsule containing 100 mg of CoQ and 400 mg of Emcompress
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Soft gelatin capsule containing 100 mg of CoQ with 400 mg of soy bean oil (Bioquinon)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Soft gelatin capsule containing 100 mg of CoQ with 20 mg of polysorbate 80, 100 mg of lecithin and 280 mg of soy bean oil
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Soft gelatin capsule containing 100 mg of CoQ with 20 mg of polysorbate 80 and 380 mg of soy bean oil
Number of subjects: 10
Study: 3287813

Group type: EXPERIMENTAL
Intervention: Rectal administration of 100 mg indomethacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous administration of 50 mg indomethacin
Number of subjects: 0
Study: 31161926

Group type: EXPERIMENTAL
Intervention: Guided Imagery (GI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Audiobook (AB) placebo treatment
Number of subjects: 0
Study: 29568743

Group type: EXPERIMENTAL
Intervention: Structured physical activity program (12 weeks, 24 exercise sessions)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Regular physical activity (control group)
Number of subjects: 50
Study: 24841502

Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted epidural steroid injections
Number of subjects: 112

Group type: COMPARATOR
Intervention: Fluoroscopic-guided epidural steroid injections
Number of subjects: 112
Study: 24446548

Group type: EXPERIMENTAL
Intervention: Escitalopram treatment for 8 weeks
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: BOLD responses to negative words
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Maximally predictive clusters of voxels
Number of subjects: 17
Study: 21641002

Group type: EXPERIMENTAL
Intervention: High energy expenditure exercise (16 kcal/kg/week)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Low energy expenditure exercise (4 kcal/kg/week)
Number of subjects: 104
Study: 18219479

Group type: EXPERIMENTAL
Intervention: Lyophilisate
Number of subjects: 44

Group type: COMPARATOR
Intervention: Eye drops
Number of subjects: 44
Study: 16579998

Group type: EXPERIMENTAL
Intervention: Measurements of serum insulin, leptin, sOB-R at fasting and during a standard oral glucose tolerance test (OGTT)
Number of subjects: 55
Study: 12061352

Group type: EXPERIMENTAL
Intervention: Ibuprofen-arginine (1 drop/kg: 6.67 mg/kg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Paracetamol (4 drops/kg: 10.65 mg/kg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ibuprofen-arginine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 100
Study: 10023515

Group type: EXPERIMENTAL
Intervention: 35% CO2 challenge
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (14 relatives free from psychiatric diagnoses)
Number of subjects: 31
Study: 7771617

Group type: EXPERIMENTAL
Intervention: 20 mg LMWH (enoxaparin) once daily
Number of subjects: 1427

Group type: COMPARATOR
Intervention: 5,000 IU SH TID
Number of subjects: 1427
Study: 2313607

Group type: EXPERIMENTAL
Intervention: Non-insulin-dependent diabetes (diet, tablet, or ultralente insulin therapy)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetes
Number of subjects: 178
Study: 379049

Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide mouthwash (Amosan), 1.7 g powder dissolved in 30 ml hot tap water, rinsed after meals for 2 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo mouthwash, rinsed after meals for 2 weeks
Number of subjects: 14
Study: 6342565

Group type: EXPERIMENTAL
Intervention: Amitriptyline hydrochloride alone, up to a maximum dosage of 300 mg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tranylcypromine alone, up to 40 mg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of amitriptyline hydrochloride, up to 150 mg/day, and tranylcypromine, up to 20 mg/day
Number of subjects: 60
Study: 30875753

Group type: EXPERIMENTAL
Intervention: Combined physical and oropharyngeal exercise program, including an eight-week urban-walking program, oropharyngeal exercises, and diet and sleep recommendations.
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group followed diet and sleep recommendations only.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Comprehensive multimodal program (including exercise, diet, and sleep recommendations).
Number of subjects: 27
Study: 29766636

Group type: EXPERIMENTAL
Intervention: Empagliflozin/Linagliptin 10/5
Number of subjects: 433

Group type: COMPARATOR
Intervention: Placebo/Linagliptin 10/5
Number of subjects: 433
Study: 27534081

Group type: EXPERIMENTAL
Intervention: TKA with individual osteotomy instrument
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional TKA
Number of subjects: 40
Study: 25056511

Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY 1021189) - once-daily oral sGC stimulator over 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22252107

Group type: EXPERIMENTAL
Intervention: Semi-skimmed milk (950 kJ)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Regular cola (900 kJ)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Energy-containing drinks (SSSD and semi-skimmed milk)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Aspartame-sweetened soft drink (ASSD)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Water
Number of subjects: 24
Study: 20810589

Group type: EXPERIMENTAL
Intervention: Combined SHA-CMHA services
Number of subjects: 505

Group type: COMPARATOR
Intervention: CMHA services alone
Number of subjects: 505
Study: 17997772

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide injections (0.2 mL of 10 mg/mL)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Incision and curettage
Number of subjects: 136

Group type: COMPARATOR
Intervention: Hot compresses (conservative treatment)
Number of subjects: 136
Study: 16329018

Group type: COMPARATOR
Intervention: Meperidine 0.5 mg/kg intravenously (group 1)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Physostigmine 10 micrograms/kg intravenously followed by meperidine 0.5 mg/kg intravenously (group 2)
Number of subjects: 44
Study: 12387462

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg
Number of subjects: 775

Group type: EXPERIMENTAL
Intervention: Tibolone 5.0 mg
Number of subjects: 775

Group type: EXPERIMENTAL
Intervention: Tibolone 1.25 mg
Number of subjects: 775

Group type: EXPERIMENTAL
Intervention: Tibolone 0.625 mg
Number of subjects: 775

Group type: EXPERIMENTAL
Intervention: Tibolone (all doses)
Number of subjects: 775

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 775
Study: 10436259

Group type: EXPERIMENTAL
Intervention: Insulin + Acarbose
Number of subjects: 40

Group type: COMPARATOR
Intervention: Insulin + Gliclazide
Number of subjects: 40
Study: 7768667

Group type: EXPERIMENTAL
Intervention: Oral budesonide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adrenocorticotropic hormone (ACTH) administration
Number of subjects: 0
Study: 2179769

Group type: EXPERIMENTAL
Intervention: Ticlopidine (500 mg per diem for 15 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Heart attack patients
Number of subjects: 12
Study: 380742

Group type: EXPERIMENTAL
Intervention: Low-dose subcutaneous heparin (5000 IU eight-hourly)
Number of subjects: 200
Study: 31187264

Group type: EXPERIMENTAL
Intervention: High flow nasal cannula at 4 L/min
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High flow nasal cannula at 6 L/min
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High flow nasal cannula at 8 L/min
Number of subjects: 18

Group type: COMPARATOR
Intervention: High flow nasal cannula (4, 6, and 8 L/min)
Number of subjects: 18
Study: 28956222

Group type: EXPERIMENTAL
Intervention: MindLight
Number of subjects: 174

Group type: COMPARATOR
Intervention: Coping Cat (CBT)
Number of subjects: 174
Study: 27805538

Group type: EXPERIMENTAL
Intervention: ABC tool intervention group
Number of subjects: 357

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 357
Study: 25095314

Group type: EXPERIMENTAL
Intervention: McInnes bleaching
Number of subjects: 30

Group type: COMPARATOR
Intervention: Enamel microabrasion
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 30
Study: 22341702

Group type: EXPERIMENTAL
Intervention: Everolimus (C(0): 50 to 90 ng/ml)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) with low dose of cyclosporine (C(0): 100 to 150 ng/ml)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Everolimus (in patients with baseline proteinuria)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Everolimus (in patients without baseline proteinuria)
Number of subjects: 34
Study: 21387802

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) combined with pharmacotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standalone pharmacotherapy
Number of subjects: 0
Study: 17557646

Group type: EXPERIMENTAL
Intervention: Ultrasound (US) treatment for ankle plantarflexor spasticity, 15 treatment sessions, three days per week, every other day.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (sham US) treatment for ankle plantarflexor spasticity, 15 treatment sessions, three days per week, every other day.
Number of subjects: 12
Study: 15802964

Group type: EXPERIMENTAL
Intervention: IFN-alpha 3 Million Units three times per week for 24 or 48 weeks and ribavirin
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: IFN-alpha and ribavirin treatment
Number of subjects: 22
Study: 12877822

Group type: EXPERIMENTAL
Intervention: Zafirlukast 40 mg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 10419221

Group type: EXPERIMENTAL
Intervention: Culturally congruent intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 7486099

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl (EP‐F)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Epidural lidocaine (EP‐L)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl (IV‐F)
Number of subjects: 30
Study: 2270301

Group type: EXPERIMENTAL
Intervention: Heparin lock changed every 72 hours (Group A)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Heparin lock left in place up to 168 hours (Group B)
Number of subjects: 301
Study: 7424031

Group type: EXPERIMENTAL
Intervention: Fenoterol (Berotec)
Number of subjects: 30

Group type: COMPARATOR
Intervention: PR-D 92
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31488342

Group type: EXPERIMENTAL
Intervention: Traditional Chinese acupressure massage (TCAM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Active recovery (AR)
Number of subjects: 20
Study: 30922713

Group type: EXPERIMENTAL
Intervention: Active tDCS (twice-daily 20-min sessions for 5 days)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 89
Study: 30027479

Group type: EXPERIMENTAL
Intervention: New mint-flavored nicotine gum (2 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New mint-flavored nicotine gum (4 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Original flavor sugar-free nicotine gum (2 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Original flavor sugar-free nicotine gum (4 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both test and reference gums
Number of subjects: 0
Study: 27402599

Group type: EXPERIMENTAL
Intervention: Nicotine (7mg nicotine patch and placebo capsule)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Methylphenidate (placebo patch and 40mg methylphenidate capsule)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo (placebo patch and capsule)
Number of subjects: 82
Study: 25175269

Group type: EXPERIMENTAL
Intervention: Diquafosol 3.0% ophthalmic solution, 1 drop, 6 times daily for 4 weeks before surgery
Number of subjects: 51

Group type: COMPARATOR
Intervention: Artificial tears, 6 times daily for 4 weeks before surgery
Number of subjects: 51
Study: 22100822

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg intravenously
Number of subjects: 52

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 52
Study: 19223653

Group type: EXPERIMENTAL
Intervention: High-GI meal
Number of subjects: 9

Group type: COMPARATOR
Intervention: Low-GI meal
Number of subjects: 9
Study: 17061043

Group type: EXPERIMENTAL
Intervention: Nuclear shape factor (highest quartile)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Nuclear size features and other shape factors
Number of subjects: 61
Study: 15163089

Group type: EXPERIMENTAL
Intervention: Thalidomide (24 mg/kg/day orally) for 1 month
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 11597547

Group type: EXPERIMENTAL
Intervention: Nocturnal enuresis group
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 106
Study: 10178338

Group type: EXPERIMENTAL
Intervention: Multi-disciplinary training programme
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (matched professionals who did not attend training)
Number of subjects: 58
Study: 7810147

Group type: EXPERIMENTAL
Intervention: 5 mg of oral diazepam
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2468266

Group type: EXPERIMENTAL
Intervention: Bladder instillation chemotherapy of anticancer agents with OK‐432 intradermal injection (group A)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Intravesical instillation chemotherapy of anticancer agents (group B)
Number of subjects: 39
Study: 31854069

Group type: EXPERIMENTAL
Intervention: Contingent cash incentives, peer mentors and usual care
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: PEth ≥50 ng/mL
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Hazardous drinking reported on AUDIT
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Heavy alcohol use by PEth
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Self-report of alcohol use
Number of subjects: 144
Study: 29304731

Group type: EXPERIMENTAL
Intervention: Volixibat (0.5 mg, 1 mg, 5 mg or 10 mg)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 27333481

Group type: EXPERIMENTAL
Intervention: Diaphragmatic stretching technique
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham-ultrasound procedure
Number of subjects: 80
Study: 25081901

Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Cisplatin + Cetuximab
Number of subjects: 103
Study: 23077933

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) for 30 min/day for 10 consecutive days
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Healthy volunteers (N=15)
Number of subjects: 26
Study: 20620002

Group type: EXPERIMENTAL
Intervention: Inelastic bandages
Number of subjects: 18

Group type: COMPARATOR
Intervention: Elastic compression stockings
Number of subjects: 18
Study: 18752510

Group type: EXPERIMENTAL
Intervention: Preserved tafluprost 0.0015% eyedrops
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Preservative-free tafluprost 0.0015% eyedrops
Number of subjects: 43
Study: 15883419

Group type: EXPERIMENTAL
Intervention: WELL diet (moderate-sodium, high-potassium, high-calcium, low-fat DASH diet)
Number of subjects: 63

Group type: COMPARATOR
Intervention: LF diet (low-fat diet)
Number of subjects: 63
Study: 12937909

Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 77

Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 77
Study: 10678560

Group type: EXPERIMENTAL
Intervention: Goserelin acetate alone
Number of subjects: 371

Group type: COMPARATOR
Intervention: Combined androgen blockade (long-term or short-term antiandrogen or short-term estrogen)
Number of subjects: 371
Study: 9103022

Group type: EXPERIMENTAL
Intervention: Vaginal cryotherapy
Number of subjects: 37
Study: 8327677

Group type: EXPERIMENTAL
Intervention: Study group (one measurement in the morning and one in the evening)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (two consecutive measurements in the morning)
Number of subjects: 10
Study: 2951960

Group type: EXPERIMENTAL
Intervention: Sufentanil (1 microgram/kg at induction, incremental doses of 10 micrograms if necessary)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isoflurane (3% prior to intubation, 0.9% during maintenance)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both anaesthetic techniques
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sufentanil and Isoflurane
Number of subjects: 40
Study: 29701037

Group type: EXPERIMENTAL
Intervention: Warming acupuncture
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 64
Study: 29911849

Group type: EXPERIMENTAL
Intervention: Ginger extract in NLC
Number of subjects: 120

Group type: COMPARATOR
Intervention: 1% Diclofenac Gel
Number of subjects: 120
Study: 26185393

Group type: EXPERIMENTAL
Intervention: JetPrep cleansing system
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard bowel cleansing
Number of subjects: 64
Study: 22995151

Group type: EXPERIMENTAL
Intervention: Knee brace and foot orthotic
Number of subjects: 16

Group type: COMPARATOR
Intervention: Knee brace
Number of subjects: 16

Group type: COMPARATOR
Intervention: Foot orthotic
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no knee brace, no foot orthotic)
Number of subjects: 16
Study: 22071279

Group type: EXPERIMENTAL
Intervention: 90 mg per day pridopidine
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: 45 mg per day pridopidine
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: 90 mg per day pridopidine (per-protocol population)
Number of subjects: 437

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 437
Study: 19016257

Group type: EXPERIMENTAL
Intervention: Antipsychotic therapy in schizophrenic women
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Antipsychotic therapy in schizophrenic men
Number of subjects: 73

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 73
Study: 16522907

Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) supplementation (3.4 g/d)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 122
Study: 12945880

Group type: EXPERIMENTAL
Intervention: Adjunct oral anticoagulation/anti‐platelet therapy (coumadin, dipyridamole, aspirin and heparin)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Adjunct anti‐platelet therapy with thienopyridin (ticlopidine, aspirin and heparin)
Number of subjects: 31